Aleix Prat: ADCs in pretreated HER2-low metastatic breast cancer
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared a recent article on LinkedIn:
“Excited to share our latest publication in Cancer Treatment Reviews led by Francesco Schettini and Guillermo Villacampa Javierre.
Our systematic review and network meta-analysis, titled Efficacy and safety of antibody-drug conjugates in pretreated HER2-low metastatic breast cancer, explores the comparative effectiveness of antibody-drug conjugates (ADCs) in this challenging patient population.
Key Highlights:
- T-DXd, SG, and Dato-DXd demonstrated comparable efficacy in PFS and OS among CT-pretreated HER2-low metastatic breast cancer patients.
- ADCs significantly outperformed standard chemotherapy in both HR+/HER2-low and TN/HER2-low subtypes.
- P-score analysis favored T-DXd for PFS and OS in HR+/HER2-low, while SG emerged as the preferred option for OS in TN/HER2-low.
- The toxicity profiles of ADCs revealed important differences, highlighting the need for personalized approaches.
This work underscores the transformative potential of ADCs and the importance of tailoring treatments based on subtype and patient characteristics.
A huge thanks to all the co-authors and collaborators who made this study possible.”
Authors: Francesco Schettini, Sabrina Nucera, Tomás Pascual, Olga Martínez-Sáez, Rodrigo Sánchez-Bayona, Benedetta Conte, Giuseppe Buono, Matteo Lambertini, Kevin Punie, Juan Miguel Cejalvo, Grazia Arpino, Paolo Vigneri, Daniele Generali, Eva Ciruelos, Javier Cortés, Alessandra Gennari, Montserrat Muñoz, Maria J. Vidal Losada, Sara M Tolaney, Aleix Prat and Guillermo Villacampa
Aleix Prat is the Director of the Cancer Institute at the Hospital Clinic of Barcelona, Head of the Translational Genomics Group at IDIBAPS, and a Professor at the University of Barcelona.
He is also a Co-Founder of REVEAL GENOMICS, S.L. His work focuses on breast cancer genomics and the development of omics-based assays for clinical application. His expertise lies in breast cancer and gene expression profiling.
More posts featuring Aleix Prat.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023